disease

Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa The stock price opened 20% higher on Wall Street after the Israeli company announced positive results from the phase 2 clinical trial of…

By Ludwig Berger (Reuters) - Sanofi Nasdaq:NASDAQ:NASDAQ:MSN’S most advanced multiple sclerosis drug failed to meet the main goal of two late-stage trials to treat recurrent forms of the disease, dimming the prospects for a broad…

Israeli biopharmaceutical decision-making company citorisonTechnologies, which develops AI-powered computational disease models for predictive insights, today announced the completion of an $80 million funding round from…

TOKYO and CAMBRIDGE, Mass., July 12, 2024 – (JCN NewsWire) – Eisai Co., Ltd. (OTC:) and Biogen Co., Ltd. (NASDAQ:) today announced the approval of the beta-amyloid (Aβ)-degrading monoclonal antibody “LEQEMBI” (generic name: lecanemab) in…

This section is Partnership Content ProvidedThe content in this section has been provided by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Globe…

(Reuters) - Eli Lilly and Company said on Monday it will acquire Morphek Holdings Inc (NASDAQ:MLS) for $3.2 billion in cash, giving the U.S. drugmaker access to an experimental drug for a type of inflammatory bowel disease. Shares of drug…

First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the ECHO Phase III trial showed AstraZeneca…

Article contentThe study, jointly conducted by researchers from Labor Quade and Johns Hopkins University School of Medicine, analyzed the long-term stability of IDM analytes in non-centrifuged peripheral blood samples to allow for increased…

BOSTON and ATLANTA - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a pharmaceutical company engaged in developing treatments for Parkinson's disease and related disorders, has announced significant advancements in its clinical trials,…

(Reuters) -Vertex Pharmaceuticals will buy Alpine Immune Sciences (NASDAQ:) for about $4.9 billion in cash, gaining access to the biotech firm's treatment for an autoimmune disease of the kidney, the companies said on Wednesday. The deal…